| Numbers (%) Mean ± SD |
---|---|
Total number of patients | 206 |
Female/male | 130/76 (63/37) |
Age (years) | 55 ± 17 |
Precapillary Pulmonary arterial hypertension: | Â |
-Idiopathic | 55 (27) |
-Associated to collagen vascular disease | 32 (16) |
-Other associated PAH | 61 (30) |
-Chronic thromboembolic PH not eligible for surgery | 58 (28) |
NYHA functional class I/II/III/IV | 1/37/104/62 (1/18/51/30)* |
BMI (kg/m2) | 25 ±5 |
Mean resting heart rate (bpm) | 82 ±14 |
Mean arterial pressure (mmHg) †| 90 ±14 |
Mean pulmonary arterial pressure (mmHg) †| 45 ±18 |
Pulmonary vascular resistance (dyn*sec*m-5) †| 775 ±464 |
Cardiac index (l/min/m2) †| 2.4 ±0.8 |
Right atrial pressure (mmHg) †| 9 ±6 |
NT-pro-BNP (ng/l, < 130) | 1826 ±2269 |
6 minute walking distance (m) | 386 ±137 |
Mean follow up (months) | 45 ±35 |
Percentage survivors at year 1, 3, 5, 7, 9 | 84/67/57/55/53 |
Medication after baseline: | Â |
-Calcium antagonist | 37 (18) |
-Prostacyclin analogues (by inhalation) | 63 (31) |
-Prostacyclin analogues (parenteral) | 8 (4) |
-Endothelin-1 receptor antagonist | 96 (47) |
-Phosphodiesterase inhibitor | 34 (17) |